Yong-Jie Lu

Professor in Molecular Oncology

Queen Mary University of London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yong-Jie Lu is a Professor in Molecular Oncology at Queen Mary University of London, UK. His research focuses on the development and applications of circulating tumour biomarkers for early cancer detection, alongside genomic evolution in prostate cancer. His recent publications explore risk stratification and prediction models for cancer outcomes across diverse populations, particularly in relation to prostate and bladder cancers.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (22)

Joseph Lachance

Associate Professor

Georgia Institute of Technology

UNITED STATES

Yong-Jie Lu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection

Genomic evolution shapes prostate cancer disease type

Novel tumor gene expression signatures improve the overall survival prediction efficiency over tumor mutation burden and PD-L1 expression in bladder carcinoma with checkpoint blockade immunotherapy.

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Circulating tumour cells for early detection of clinically relevant cancer

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.

A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer.

Collaborators (22)

Joseph Lachance

Nora Pashayan

FEI CHEN

Chun Chieh Fan

Paul Townsend

Minh-Phuong Huynh-Le

Aswin George Abraham

Tyler Seibert

Andy Lynch

Karina Dalsgaard Sørensen

Daniel Brewer

Yili Xu

Robert Bristow

Manuel António Rodrigues Teixeira

Rosalind Eeles

David Wedge

Burcu F Darst

ANNE WARREN

Elaine Ostrander

Luc Multigner

Catharine West

Ian Mills

Make your next move.